CO5640094A2 - Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis de tumor - Google Patents
Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis de tumorInfo
- Publication number
- CO5640094A2 CO5640094A2 CO05119402A CO05119402A CO5640094A2 CO 5640094 A2 CO5640094 A2 CO 5640094A2 CO 05119402 A CO05119402 A CO 05119402A CO 05119402 A CO05119402 A CO 05119402A CO 5640094 A2 CO5640094 A2 CO 5640094A2
- Authority
- CO
- Colombia
- Prior art keywords
- necrosis factor
- tumor necrosis
- alphus
- pharmaceutical composition
- composition including
- Prior art date
Links
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title abstract 3
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000002464 receptor antagonist Substances 0.000 abstract 2
- 229940044551 receptor antagonist Drugs 0.000 abstract 2
- YNZTXTGFUQRXMU-UHFFFAOYSA-N [2-(1-adamantylamino)-2-oxo-1-phenylethyl] propanoate Chemical group C1C(C2)CC(C3)CC2CC13NC(=O)C(OC(=O)CC)C1=CC=CC=C1 YNZTXTGFUQRXMU-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0312321A GB0312321D0 (en) | 2003-05-29 | 2003-05-29 | New combination |
| SE0301655A SE0301655D0 (sv) | 2003-06-05 | 2003-06-05 | New combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5640094A2 true CO5640094A2 (es) | 2006-05-31 |
Family
ID=33492248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05119402A CO5640094A2 (es) | 2003-05-29 | 2005-11-24 | Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis de tumor |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070032465A1 (https=) |
| EP (1) | EP1633401A1 (https=) |
| JP (1) | JP2007501270A (https=) |
| KR (1) | KR20060037258A (https=) |
| AR (1) | AR044452A1 (https=) |
| BR (1) | BRPI0410739A (https=) |
| CA (1) | CA2526883A1 (https=) |
| CO (1) | CO5640094A2 (https=) |
| IS (1) | IS8188A (https=) |
| MX (1) | MXPA05012705A (https=) |
| NO (1) | NO20056131L (https=) |
| RU (1) | RU2350354C2 (https=) |
| TW (1) | TW200507829A (https=) |
| UY (1) | UY28335A1 (https=) |
| WO (1) | WO2004105798A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| US20070281931A1 (en) * | 2003-05-29 | 2007-12-06 | Nigel Boughton-Smith | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate |
| WO2004105797A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
| SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| JP5134530B2 (ja) * | 2005-03-07 | 2013-01-30 | ライラ ニュートラシューティカルズ | ボスウェル酸及び選択的に濃縮したボスウェル酸の新規な塩、ならびにそのための方法 |
| GB0919594D0 (en) | 2009-11-09 | 2009-12-23 | Glaxo Group Ltd | Compounds |
| EP2542670A2 (en) | 2010-03-05 | 2013-01-09 | President and Fellows of Harvard College | Induced dendritic cell compositions and uses thereof |
| US9538710B2 (en) | 2010-04-01 | 2017-01-10 | Tony Wayne Covely | Crop product tracking system and method |
| US10444122B2 (en) | 2010-04-01 | 2019-10-15 | Agri-Labs Holdings Llc | Soil sample tracking system and method |
| US20140171445A1 (en) * | 2011-08-04 | 2014-06-19 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Treatment and prevention of diseases mediated by microorganisms via drug-mediated manipulation of the eicosanoid balance |
| EP2849723B1 (en) | 2012-05-18 | 2018-05-02 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
| KR102035463B1 (ko) * | 2018-02-14 | 2019-11-26 | 연세대학교 산학협력단 | 암 줄기세포의 치료용 약학 조성물 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3471491A (en) * | 1967-08-28 | 1969-10-07 | Squibb & Sons Inc | Adamantyl-s-triazines |
| US3464998A (en) * | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
| US4349552A (en) * | 1978-10-30 | 1982-09-14 | Fujisawa Pharmaceutical Company, Ltd. | 5-Fluorouracil derivatives, and their pharmaceutical compositions |
| US4751292A (en) * | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
| US5399564A (en) * | 1991-09-03 | 1995-03-21 | Dowelanco | N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides |
| CZ296163B6 (cs) * | 1996-05-20 | 2006-01-11 | Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV | |
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| CZ20013608A3 (cs) * | 1999-04-09 | 2002-05-15 | Astrazeneca Ab | Adamantanové deriváty |
| SE9904505D0 (sv) * | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| GB0013737D0 (en) * | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| CZ20042A3 (en) * | 2001-07-02 | 2004-04-14 | Akzo Nobel N. V. | Tetrahydroquinoline derivatives |
| WO2003042190A1 (en) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| SE0103836D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| US6908939B2 (en) * | 2001-12-21 | 2005-06-21 | Galderma Research & Development S.N.C. | Biaromatic ligand activators of PPARγ receptors |
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| SE0300445D0 (sv) * | 2003-02-18 | 2003-02-18 | Astrazeneca Ab | New combination |
| SE0300480D0 (sv) * | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| US20070281931A1 (en) * | 2003-05-29 | 2007-12-06 | Nigel Boughton-Smith | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate |
| WO2004105797A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
-
2004
- 2004-05-27 MX MXPA05012705A patent/MXPA05012705A/es not_active Application Discontinuation
- 2004-05-27 CA CA002526883A patent/CA2526883A1/en not_active Abandoned
- 2004-05-27 KR KR1020057022669A patent/KR20060037258A/ko not_active Ceased
- 2004-05-27 BR BRPI0410739-0A patent/BRPI0410739A/pt not_active IP Right Cessation
- 2004-05-27 WO PCT/SE2004/000817 patent/WO2004105798A1/en not_active Ceased
- 2004-05-27 TW TW093115142A patent/TW200507829A/zh unknown
- 2004-05-27 RU RU2005136131/15A patent/RU2350354C2/ru not_active IP Right Cessation
- 2004-05-27 JP JP2006532213A patent/JP2007501270A/ja active Pending
- 2004-05-27 EP EP04735147A patent/EP1633401A1/en not_active Withdrawn
- 2004-05-27 US US10/558,354 patent/US20070032465A1/en not_active Abandoned
- 2004-05-28 AR ARP040101848A patent/AR044452A1/es unknown
- 2004-05-28 UY UY28335A patent/UY28335A1/es unknown
-
2005
- 2005-11-24 CO CO05119402A patent/CO5640094A2/es not_active Application Discontinuation
- 2005-12-20 IS IS8188A patent/IS8188A/is unknown
- 2005-12-22 NO NO20056131A patent/NO20056131L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200507829A (en) | 2005-03-01 |
| AU2004243137A1 (en) | 2004-12-09 |
| IS8188A (is) | 2005-12-20 |
| MXPA05012705A (es) | 2006-02-08 |
| BRPI0410739A (pt) | 2006-06-27 |
| AR044452A1 (es) | 2005-09-14 |
| EP1633401A1 (en) | 2006-03-15 |
| US20070032465A1 (en) | 2007-02-08 |
| UY28335A1 (es) | 2004-12-31 |
| JP2007501270A (ja) | 2007-01-25 |
| CA2526883A1 (en) | 2004-12-09 |
| RU2005136131A (ru) | 2006-07-27 |
| NO20056131L (no) | 2006-02-28 |
| WO2004105798A1 (en) | 2004-12-09 |
| KR20060037258A (ko) | 2006-05-03 |
| RU2350354C2 (ru) | 2009-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5640094A2 (es) | Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis de tumor | |
| AR033555A1 (es) | Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| CL2004000889A1 (es) | COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION. | |
| AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| CY1111458T1 (el) | Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης | |
| PT1207756E (pt) | Utilizacao de espinosade ou de uma formulacao que compreende espinosade | |
| ES2190205T3 (es) | Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda. | |
| BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
| CY1107819T1 (el) | Φαρμακευτικη διαμορφωση της ολανζαπινης | |
| BRPI0414558A (pt) | composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide | |
| AR025330A1 (es) | Combinacion de sustancias activas con clonidina | |
| BRPI0511420A (pt) | fosforodiamidatos de sulfoniletila | |
| UY28007A1 (es) | Tratamiento terapeutico | |
| ITRM20030363A0 (it) | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse. | |
| AR041595A1 (es) | Tratamiento terapeutico | |
| UY27753A1 (es) | Formulación farmacéutica que comprende melatonina. | |
| UY29952A1 (es) | Composiciones faramacéuticas que comprenden 4-(4-fluoro-2-metil-1h-indol-5-iloxi)-6-metoxi-7-(3-(pirrolidin-1-il)propoxi)quinazolina o una sal farmacéuticamente aceptable del mismo, procesos de preparación y uso | |
| CA2385755A1 (en) | Prevention of colorectal cancer | |
| CL2004001317A1 (es) | Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h | |
| MXPA05009849A (es) | Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2. | |
| CL2008002555A1 (es) | Composicion farmaceutica que comprende un compuesto de levosimendan y un segundo ingrediente activo un antagonista del receptor de angiotensiva ii; un kit farmaceutico que comprende dicha composicion; y su uso para la prevencion o la inhibicion de apoplejia. | |
| CY1107227T1 (el) | Θεραπεια αυτοανοσων νοσων με εκχυλισμα αμερικανικου γκινσενγκ | |
| AR046955A1 (es) | Preparacion efervescente de una sustancia basica farmaceuticamente activa | |
| CL2004001262A1 (es) | Composicion farmaceutica que comprende lamivudina, zidovudina y efavirenz, o derivados de ellos; kit farmaceutico; procedimiento para su preparacion; y uso en la preparacion de un medicamento para el tratamiento o prevencion de infecciones virales, e |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |